The 340B drug savings program must be reformed, Health and Human Services Secretary Alex Azar said today at a 340B conference in Washington, D.C. Azar spoke about the need for “greater transparency surrounding how these [340B] discounts are being used” and “reforms to reduce the gap between discounted prices and the reimbursement provided.” In addition, Azar said change is coming for the larger issue of prescription drug pricing, “whether it’s painful or not for pharmaceutical companies.” He spoke about the administration’s request for information , which was released in May, on ways to lower drug prices and reduce out-of-pocket costs for consumers. “Something must be done about these skyrocketing list prices, and yet the system that has been built makes that nearly impossible,” he said. “Everyone in the system, from drug companies to pharmacy benefit managers to drug wholesalers makes their money as a share of list prices.”

Related News Articles

Headline
The Department of Health and Human Services May 20 announced it has identified specific pricing targets for pharmaceutical manufacturers to meet to satisfy…
Headline
A U.S. district court judge for the District of Columbia May 15 ruled the Department of Health and Human Services must preapprove the use of 340B “rebate…
Headline
The Centers for Medicare & Medicaid Services May 12 released draft guidance for the third round of negotiations for the Medicare Drug Price Negotiation…
Headline
The AHA May 14 filed an amicus brief in the U.S. District Court for the District of South Dakota in defense of the state’s 340B contract pharmacy law…
Headline
The AHA May 9 urged the Department of Health and Human Services to deny drug companies’ requests to approve their unlawful 340B rebate models. “The 340B…
Headline
The White House May 12 released an executive order to reduce prescription drug costs by allowing consumers to make direct purchases from drug manufacturers at…